Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Randomized Controlled Trial of Lidocaine Occipital Nerve Blocks to Treat Status Migrainosus in Children/Adolescents
Headache
S22 - Advances in Migraine and Therapeutics (1:00 PM-1:12 PM)
001

Peripheral nerve blocks (PNBs), injections of local anesthetics over branches of the occipital and/or trigeminal nerves, have been associated with benefit for pediatric headaches in case series.  PNBs are used by 80% of pediatric headache specialists, but have not been tested in a randomized pediatric trial.   

To test the efficacy of greater occipital nerve blocks with lidocaine in children/adolescents with acute migraine in a randomized control trial. 

We conducted a randomized, double-blind trial of bilateral occipital nerve blocks with lidocaine versus saline for treatment of acute, severe headache refractory to usual therapies.  Participants were ages 10-21 years with a migraine flare of 24hrs to 3 months duration with insufficient response to other treatments for status migrainosus.  All participants had lidocaine cream applied for 30min as a run-in step and could decline injections if they experienced sufficient benefit from cream alone.  The injection medication was block randomized by episodic versus chronic migraine.  The primary comparison was difference in change in pain score between lidocaine and saline injection groups. 

Sixty-four youth signed consent and assent, and 58 were eligible.  Mean age was 16±1.8 years; reported gender was female for 44, male for 11, and non-binary or transgender for 3.  Topical lidocaine cream lead-in resulted in mean decrease in pain score of 0.2±0.9 points on 0-10 scale, and all participants proceeded to randomized injection.  The lidocaine injection group reported mean decrease of 2.3±1.9 points on 0-10 scale and the saline injection group reported mean decrease of 1.1±1.9 points (t-test, p=0.01).  Of those injected, 22/29 getting lidocaine reported at least partial relief in severity or location of pain compared to 14/29 getting saline (X2 p=0.03)

Greater occipital nerve injections with lidocaine resulted in a significantly larger drop in pain score compared to saline injections for youth with status migrainosus. 

Authors/Disclosures
Christina L. Szperka, MD (Children's Hospital of Philadelphia)
PRESENTER
The institution of Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Szperka has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Upsher Smith. The institution of Dr. Szperka has received research support from NINDS. The institution of Dr. Szperka has received research support from PCORI. The institution of Dr. Szperka has received research support from International Headache Society.
Blanca Marquez de Prado No disclosure on file
Jesse Hsu (University of Pennsylvania) No disclosure on file
Amy Gelfand, MD (UCSF) Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Headache Society. The institution of an immediate family member of Dr. Gelfand has received research support from Roche/Genentech. The institution of an immediate family member of Dr. Gelfand has received research support from Vigil Neuroscience. The institution of Dr. Gelfand has received research support from UCSF Resource Allocation Program. The institution of an immediate family member of Dr. Gelfand has received research support from NIH/NINDS. The institution of an immediate family member of Dr. Gelfand has received research support from National MS Society. The institution of Dr. Gelfand has received research support from PCORI. Dr. Gelfand has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as a Expert Witness with United States Department of Health and Human Services, Vaccine Injury Compensation Program. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Headache Cooperative of the Pacific. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Taiwan Headache Society. An immediate family member of Dr. Gelfand has a non-compensated relationship as a Clinical Trial Steering Committee Member with Roche/Genentech that is relevant to AAN interests or activities.
Dana Haagen No disclosure on file
Danielle J. Kellier The institution of Ms. Kellier has received research support from National Institute of Neurological Disorders and Stroke.
Dennis J. Dlugos, MD Dr. Dlugos has received research support from NIH. The institution of Dr. Dlugos has received research support from The Epilepsy Study Consortium.
Nichelle Raj No disclosure on file
Andrew D. Hershey, MD, PhD, FAHS, FAAN The institution of Dr. Hershey has received personal compensation in the range of $0-$499 for serving as a Consultant for Amgen. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Upsher-Smith. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Hershey has received research support from Amgen. The institution of Dr. Hershey has received research support from NIH, NINDS. The institution of Dr. Hershey has received research support from Bioahaven. The institution of Dr. Hershey has received research support from Upsher-Smith. Dr. Hershey has received publishing royalties from a publication relating to health care.
John T. Farrar, MD (Univ of PA Medical Center) Dr. Farrar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharma. Dr. Farrar has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for PharamcoEpidemiology and Drug Safety. The institution of Dr. Farrar has received research support from Food and Drug Administration . The institution of Dr. Farrar has received research support from NIH .